NASDAQ: PSTVPlus Therapeutics Inc Stock
$4.05+0.07 (+1.76%)
Updated Jul 6, 2026
PSTV Price
$4.05
Fair Value Price
N/A
Market Cap
$27.88M
52 Week Low
$2.90
52 Week High
$23.50
P/E
-2.61x
P/B
2.33x
P/S
5.21x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.18M
Earnings
-$11.93M
Gross Margin
100%
Operating Margin
-232.81%
Profit Margin
-230.2%
Debt to Equity
0.67
Operating Cash Flow
-$21M
Beta
0.72
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PSTV Overview
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PSTV's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important PSTV news, forecast changes, insider trades & much more!
PSTV News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PSTV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PSTV is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PSTV is good value based on its book value relative to its share price (2.33x), compared to the US Biotechnology industry average (5.58x)
P/B vs Industry Valuation
PSTV is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PSTV due diligence checks available for Premium users.
Valuation
PSTV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.61x
Industry
18.36x
Market
6.94x
PSTV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.33x
Industry
5.58x
PSTV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PSTV's financial health
Profit margin
Revenue
$1.0M
Net Income
-$6.9M
Profit Margin
-675.7%
PSTV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PSTV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$19.9M
Liabilities
$8.0M
Debt to equity
0.67
PSTV's short-term assets ($18.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PSTV's short-term assets ($18.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PSTV's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PSTV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.2M
Investing
-$8.5M
Financing
$9.0M
PSTV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PSTV vs Biotech Stocks
Plus Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.